Abstract: Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group,in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitrogen or oxygen atom, ##STR3## in which R.sub.2 and R.sub.

Abstract: A cephalosporin derivative represented by the formula ##STR1## wherein R is an organic residue known on .beta.-lactam antibiotics and Q is a radical of ##STR2## dotted-line means a possible double bond, R.sub.1 is hydrogen or monovalent substituent, R.sub.2, R.sub.3 and R.sub.4 are mono-valent substituent, respectively,a salt thereof, a process for the manufacture thereof and a pharmaceutical agent comprising same.

Abstract: 1,4-Dihydropyridine derivatives represented by the formula ##STR1## wherein one of R.sup.1 and R.sup.2 is cycloalkylmethyl group and the other is a group of ##STR2## in which R.sup.3 is hydrogen atom or lower alkyl group and R.sup.4 is hydrogen atom, hydroxyl radical, carboxyl radical, alkoxycarbonyl group, carbamoyl radical, phenyl radical, substituted phenyl radical or trialkylsilyl group, or R.sup.3 and R.sup.4 may be bonded each other, and n and m are an integer of 1 to 6, respectively salts thereof, a process for the preparation of same as well as a pharmaceutical agent comprising the compound or salt, as an effective ingredient.

Abstract: Novel organo-silicone compounds represented by the formula, ##STR1## wherein R is hydrogen, halogen or alkyl group, R.sup.1, R.sup.2 and R.sup.3 are alkyl group, alkoxy group, phenyl radical, substituted phenyl radical, alkylcarbonyloxy group, or trialkylsilyloxy group, respectively, R.sup.4 is hydrogen, alkyl or alkenyl grup, and m and n are an integer, respectively but those do not represent same integer of 2, when all of R.sup.1, R.sup.2 and R.sup.3 represents methyl radical, a process for the manufacture of the compounds, and an anti-tumor agent which comprises as an effective component, at least one of the compounds.

Abstract: A spiro-3-heteroazolidine compound and agents comprising that compound which have special utility as an antidiabetic composition and as a substance to inhibit aldose reductase enzyme activity.

Abstract: Novel pyrrolizidine compounds represented by the formula ##STR1## wherein R is a radical of ##STR2## R.sup.1 is hydrogen, halogen, alkyl group, alkoxy group, alkanoyl group, trifluoromethyl radical, trimethylsilyl radical or ##STR3## R.sup.2 and R.sup.3 are same or different and are hydrogen or alkyl group, respectively, R.sup.4 is hydrogen, halogen, alkyl group or alkoxy group and m is an integer of 0 to 5,salts thereof, a process for the preparation of same as well as a pharmaceutical agent comprising same.

Abstract: Novel 2-oxopyrrolidine compounds represented by the formula ##STR1## wherein R.sup.1 and R.sup.2 are hydrogen or alkyl group, respectively, A is alkylene group or phenyl substituted alkylene group, and B is alkylene group,or a salt thereof, a process for the preparation thereof, and a pharmaceutical agent comprising the compound or salt as an effective component.

Abstract: A novel resolution method of a racemic mixture, wherein four kinds of salts are dissolved in a resolving solvent to fractionally crystallize a desired optically active isomer through an exchange reaction between counter ions.

Abstract: A novel organosilicon compound represented by a formula ##STR1## wherein A is methylene, carbonyl or sulfonyl group; R, R.sub.1 and R.sub.2 are alkyl group, respectively; R.sub.3 is alkyl, substituted alkyl, alkenyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl, pyridyl, substituted pyridyl, furyl, substituted furyl, thienyl, substituted thienyl group or cycloalkyl group together with the substituent A; R.sub.4 is hydrogen, alkyl or alkenyl group; and R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11 and R.sub.12 are hydrogen, alkyl or substituted alkyl, respectively,a non-toxic salt thereof, a process for the preparation of said compound or salt, as well as an antitumor agent comprising as an effective agent at least one of said compound and salt.

Abstract: A novel polymer-metal complex containing quaternary nitrogen atoms, which is obtained by subjecting polyethylenepolyamine or polyethyleneimine to a reaction with a bifunctional compound represented by the formulaY--A--Zwherein Y and Z are same or different and are --CH.sub.2 X, --CH(OH)CH.sub.2 X or ##STR1## group, respectively, A is a single bond, --(CH.sub.2).sub.m --, --CH.sub.2 --O--CH.sub.2 -- or --CH.sub.2 --O--(CH.sub.2).sub.k --O--CH.sub.2 -- group, X is chlorine, bromine or iodine atom, m is an integral of 1 to 3, and k is an integral of 1 to 4, and then subjecting the resulting cross-linked polymer to a coordination of a polyvalent metal ion, a salt thereof, a process for the preparation thereof and a pharmaceutical agent comprising the same.

Abstract: A process for the preparation of 4-chloro-2-nitrobenzonitrile, which comprises a step for subjecting 2,5-dichloronitrobenzene to a reaction with copper (I) cyanide.

Abstract: The present invention relates to prostaglandin analogues of the general formula: ##STR1## [wherein A represents a grouping of the formula: ##STR2## X represents trans-vinylene or ethylene and Y represents cis-vinylene or ethylene, R represents a group of the formula --COOR.sup.4, in which R.sup.4 represents hydrogen or straight- or branched-chain alkyl of 1 to 12 carbon atoms, or a group of the formula --CH.sub.2 OR.sup.5, in which R.sup.5 represents hydrogen or alkylcarbonyl of 2 to 5 carbon atoms and R.sup.1, R.sup.2 and R.sup.3, which may be the same or different, each represent hydrogen, straight- or branched-chain alkyl of 1 to 12 carbon atoms, or an aryl group unsubstituted or substituted by one, two or three substituents selected from alkyl, alkoxy, alkylthio, monoalkylamino and dialkylamino groups and halogen atoms, the alkyl groups or moieties of the said groups containing from 1 to 5 carbon atoms in a straight- or branched-chain, with the proviso that at least one of the symbols R.sup.1, R.sup.

Abstract: The invention relates to prostaglandin analogues of the general formula: ##STR1## (wherein A represents a grouping of the formula: ##STR2## B represents an alkylene group containing from 1 to 7 carbon atoms or a group ##STR3## (wherein the group --(CH.sub.2).sub.n --may be attached to the ortho, meta or para position of the phenyl ring and m and n, which may be the same or different, each represent an integer from 1 to 5 inclusive, the sum of the integers represented by m and n being from 2 to 6 inclusive), X represents ethylene or cis-vinylene, Y represents ethylene or trans-vinylene, W represents ethylene or trans-vinylene, Z represents a halogen atom, and R.sup.1 represents a hydrogen atom or an alkyl group containing from 1 to 12 carbon atoms) and cyclodextrin clathrates of such acids and esters and, when R.sup.1 represents a hydrogen atom, non-toxic salts thereof, which possess characteristic prostaglandin-like properties.

Abstract: A process for preparing an .alpha.-substituted phenylalkanecarboxylic acid, having useful pharmaceutical properties such as analgesic, anti-inflammatory and anti-pyretic properties, from the corresponding ethylidenecyanoacetate by oxidation, hydrolysis, decarboxylation and oxidation.

Abstract: 5-Fluorouracil derivatives and a process for their preparation are provided. The 5-fluorouracil derivatives according to the invention have the general formula: ##STR1## R.sub.1 and R.sub.2 are the same or different and are hydrogen or ##STR2## with the proviso that both R.sub.1 and R.sub.2 are not hydrogen at the same time. A.sub.1, A.sub.2 and A.sub.3 are independently selected from hydrogen, and optionally substituted alkoxy and phenyloxy; at least one of A.sub.1, A.sub.2 and A.sub.3 being other than hydrogen. The 5-fluorouracil derivative is prepared by condensing 5-fluorouracil with a halide of the formula: ##STR3## in the presence of a base. The 5-fluorouracils according to the invention show anti-tumor activity.

Abstract: Prostaglandin analogues of the formula: ##STR1## wherein A represents a grouping of the formula: ##STR2## X represents trans-vinylene or ethylene and Y represents cis-vinylene or ethylene, R represents hydrogen or alkyl of 1 through 12 carbon atoms, R.sup.1, R.sup.2 and R.sup.3 represent hydrogen, or alkyl of 1 through 12 carbon atoms or an aryl group, with the proviso that at least one of the symbols R.sup.1, R.sup.2 and R.sup.3 represents an alkyl or aryl group, are new compounds possessing useful pharmacological properties; they are especially useful for the treatment of gastric ulceration.

Abstract: Prostaglandin analogues of the formula: ##STR1## wherein A represents a grouping of the formula: ##STR2## X represents trans-vinylene or ethylene and Y represents cis-vinylene or ethylene, R represents hydrogen or alkyl of 1 through 12 carbon atoms, R.sup.1, R.sup.2 and R.sup.3 represent hydrogen, or alkyl of 1 through 12 carbon atoms or an aryl group, with the proviso that at least one of the symbols R.sup.1, R.sup.2 and R.sup.3 represents an alkyl or aryl group, are new compounds possessing useful pharmacological properties; they are especially useful for the treatment of gastric ulceration.